Seven new drugs were approved for treatment of neurological disorders, including Parkinson disease, multiple sclerosis, and amyotrophic lateral sclerosis.
Biogen and Sage Terminate Development of SAGE-324 Following Disappointing Phase 2 Data
Episode 119: Utilizing the Syn-One Test to Diagnose Parkinson Disease
NeuroVoices: David Shprecher, DO, MSci, FAAN, on Current and Future Directions in Biomarker Testing for Atypical Parkinsonism
Episode 117: 2024 Consortium of Multiple Sclerosis Centers Annual Meeting Highlights
Utility of Helius’ Neuromodulation System to Treat Gait in Multiple Sclerosis
Spinal Movement Disorders Prevalent in Non-MS Demyelinating Disorders of Spinal Cord